Probable predictive biomarkers for tumor response to mTOR inhibitors, as have been explained in glioblastoma, breast and prostate most cancers cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Therefore, this info relies on preclinical assays, determined by in vitro cultured tumor cell traces, which https://nilest742kpt5.theobloggers.com/profile